Gilberto Lopes, Chief of the medical oncology division and professor of clinical medicine at the Miller School of Medicine, shared an article by Luís F Leite da Silva, et al. on X:
“Our meta-analysis aggregates data from more the 30 studies comprising 3000+ patients, showing that ctDNA decrease and clearance are strongly associated with PFS and OS in lung cancer.
Results hold true for targeted treatments and immunotherapy!
Time is ripe to include as outcome in prospective studies so we can incorporate in decision making and drug approval process – FDA Oncology.”
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Authors: Luís F Leite da Silva, et al.
